journal article·2024-09

Tunneling nanotubes mediate KRas transport: Inducing tumor heterogeneity and altering cellular membrane mechanical properties

Yawen Zheng, Jiangtao Li, Dadi Xu, Liu Liu, Yuyao Li, Jing Yi, Jiayao Dong, Daiwen Pang, Hongwu Tang

Acta Biomaterialia· Volume 185
Publisher page

Abstract

Mutation in oncogene KRas plays a crucial role in the occurrence and progression of numerous malignant tumors. Malignancy involves changes in cell mechanics for extensive cellular deformation during metastatic dissemination. We hypothesize that oncogene KRas mutations are intrinsic to alterations in cellular mechanics that promote malignant tumor generation and progression. Here, we demonstrate the use of optical tweezers coupled with a confocal fluorescence imaging system and gene interference technique to reveal that the mutant KRas protein can be transported between homogeneous and heterogeneous tumor cells by tunneling nanotubes (TNTs), resulting in a significant reduction of membrane tension and acceleration of membrane phospholipid flow in the recipient cells. Simultaneously, the changes in membrane mechanical properties of the tumor cells also enhance the metastatic and invasive ability of the tumors, which further contribute to the deterioration of the tumors. This finding helps to clarify the association between oncogene mutations and changes in the mechanical properties of tumor cells, which provides a theoretical basis for the development of cancer treatment strategies. STATEMENT OF SIGNIFICANCE: Here, we present a laser confocal fluorescence system integrated with optical tweezers to observe the transfer of mutant KRasG12D protein from mutant cells to wild-type cells through TNTs. Malignancy involves changes in cell mechanics for extensive cellular deformation during metastatic dissemination. Our results demonstrate a significant decrease in membrane tension and an increase in membrane phospholipid flow in recipient cells. These alterations in mechanical properties augment the migration and invasive capabilities of tumor cells, contributing to tumor malignancy. Our findings propose that cellular mechanical properties could serve as new markers for tumor development, and targeting membrane tension may hold potential as a therapeutic strategy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cellular Mechanics and Interactions · Microtubule and mitosis dynamics · Erythrocyte Function and Pathophysiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Targeting the untargetable KRAS in cancer therapy10.1016/j.apsb.2019.03.002 ↗
2. A compendium of mutational cancer driver genes10.1038/s41568-020-0290-x ↗
3. Drugging RAS: know the enemy
4. The current state of the art and future trends in RAS-targeted cancer therapies10.1038/s41571-022-00671-9 ↗
5. Tunneling nanotubes: the fuel of tumor progression?10.1016/j.trecan.2020.04.012 ↗
6. Intercellular transfer of oncogenic KRAS via tunneling nanotubes introduces intracellular mutational heterogeneity in colon cancer cells10.3390/cancers11070892 ↗
7. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells10.1073/pnas.1017667108 ↗
8. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS*10.1074/mcp.M112.022806 ↗
9. Tunneling nanotubes mediated microRNA-155 intercellular transportation promotes bladder cancer cells’ invasive and proliferative capacity10.2147/IJN.S217277 ↗
10. Tunneling-nanotube development in astrocytes depends on p53 activation10.1038/cdd.2010.147 ↗
11. Tunneling nanotubes promote intercellular mitochondria transfer followed by increased invasiveness in bladder cancer cells10.18632/oncotarget.14695 ↗
12. Rab11a mediates cell-cell spread and reassortment of influenza A virus genomes via tunneling nanotubes10.1371/journal.ppat.1009321 ↗
13. Tunneling nanotubes provide a route for SARS-CoV-2 spreading10.1126/sciadv.abo0171 ↗
14. Influenza virus exploits tunneling nanotubes for cell-to-cell spread10.1038/srep40360 ↗
15. The Hallmarks of cancer10.1016/S0092-8674(00)81683-9 ↗
16. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
17. The fundamental role of mechanical properties in the progression of cancer disease and inflammation10.1088/0034-4885/77/7/076602 ↗
18. Stiffness of cancer cells measured with an AFM indentation method10.1016/j.jmbbm.2015.04.030 ↗
19. The nanomechanical signature of breast cancer10.1038/nnano.2012.167 ↗
20. Mapping intracellular mechanics on micropatterned substrates10.1073/pnas.1605112113 ↗
21. Cell motility and local viscoelasticity of fibroblasts10.1529/biophysj.104.053462 ↗
22. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence10.1529/biophysj.104.045476 ↗
23. Single cell mechanotype and associated molecular changes in urothelial cell transformation and progression10.3389/fcell.2020.601376 ↗
24. Elasticity of normal and cancerous human bladder cells studied by scanning force microscopy10.1007/s002490050213 ↗
25. Multiscale rheology of glioma cells10.1016/j.biomaterials.2021.120903 ↗
26. Comparison of mechanical properties of normal and malignant thyroid cells10.1016/j.micron.2012.03.023 ↗
27. The nanomechanical signature of liver cancer tissues and its molecular origin10.1039/C5NR02192H ↗
28. Homeostatic membrane tension constrains cancer cell dissemination by counteracting BAR protein assembly10.1038/s41467-021-26156-4 ↗
29. Biophysical approaches for applying and measuring biological forces
30. Dynamics of membrane tethers reveal novel aspects of cytoskeleton-membrane interactions in axons10.1016/j.bpj.2014.11.3480 ↗
31. unexpected membrane dynamics unveiled by membrane nanotube extrusion10.1016/j.bpj.2013.01.051 ↗
32. An excitable Ras/PI3K/ERK signaling network controls migration and oncogenic transformation in epithelial cells10.1016/j.devcel.2020.08.001 ↗
33. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer10.1016/S1470-2045(10)70209-6 ↗
34. Nanotubular highways for intercellular organelle transport10.1126/science.1093133 ↗
35. Structurally distinct membrane nanotubes between human macrophages support long-distance vesicular traffic or surfing of bacteria110.4049/jimmunol.177.12.8476 ↗
36. Z.-G. Wang, S.-L. Liu, Z.-Q. Tian, Z.-L. Zhang, H.-W. Tang, D.-W. Pang, Myosin-driven intercellular transportation of wheat germ agglutinin mediated by membrane nanotubes between human lung cancer cells, 6 (2012) 9.10.1021/nn303729r ↗
37. Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence10.1023/A:1023406224028 ↗
38. Vesicle traffic through intercellular bridges in DU 145 human prostate cancer cells10.1111/j.1582-4934.2004.tb00328.x ↗
39. Coupled excitable Ras and F-actin activation mediates spontaneous pseudopod formation and directed cell movement10.1091/mbc.e16-10-0733 ↗
40. Cell protrusions and contractions generate long-range membrane tension propagation10.1016/j.cell.2023.05.014 ↗
41. Membrane tension and cytoskeleton organization in cell motility
42. Exploring membrane mechanics: the role of membrane-cortex attachment in cell dynamics10.1016/j.ceb.2023.102173 ↗
43. A convergence-based framework for cancer drug resistance10.1016/j.ccell.2018.03.025 ↗
44. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy10.1186/s13073-017-0431-3 ↗
45. Therapeutic strategies to target RAS-mutant cancers10.1038/s41571-018-0105-0 ↗
46. Sotorasib for lung cancers with KRAS p.G12C mutation10.1056/NEJMoa2103695 ↗
47. A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus Irinotecan or the MEK inhibitor PD-0325901 in advanced cancer10.1007/s11523-017-0530-5 ↗
48. Tunneling nanotubular expressways for ultrafast and accurate M1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma